Recent news reports reveal that BMS and IFM Therapeutics have signed an agreement in which Bristol-Myers Squibb will acquire full rights to IFM’s NLRP3 and STING agonist programs in an effort to target innate immunity pathways that could potentially assist the body’s natural defenses in recognizing tumors and attacking them, expanding and complementing Bristol-Myers Squibb’s immuno-oncology portfolio. Reports claim BMS …
Pharma Coders – Naloxone Prescription Reform In Maine
Narcan, the brand name of naloxone, a drug used to reverse overdose in those who have taken opioids, will become available in Maine without a prescription from a doctor, as one keyword added to the bill last month would make it possible for pharmacists to prescribe the medicine. News reports state Assistant Attorney General, Andrew Black, said in written testimony …
FDA’s Decision To Delay Serialization Regulations Indicates Stragglers
Up until recently, the deadline for pharmaceutical companies and contract manufacturers to meet serialization regulations regarding assignment of product identifiers to packages was November 26 of this year. Now the FDA has made the decision to push this date back to November of 2018, a one year delay. Many industry representatives feel this delay indicates that manufacturers in both the …
Pharma News – Takeda’s Instanyl DoseGuard Controls Opioid Dosing
Everywhere we turn today, we hear news about the “opioid” crisis; lives have been impacted throughout the U.S. and North America as some who’ve taken opioids for pain management have become addicted, while others get their “fix” on the streets. Recently in pharma news, it was announced that Takeda Pharmaceuticals International AG will use an e-Lockout device that essentially limits …
Pharma News – Novartis Given Green Light On Biosimilar Of Neupogen
Recently in pharma news, in a 9 – 0 ruling, the U.S. Supreme Court overturned a lower court’s decision that prevented Novartis from selling its biosimilar version of Neupogen, a drug made by California-based Amgen Inc. Prior to the ruling, biosimilar drugs (also referred to as “copycat” versions of other drugs) could not be put on the market until six …